Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas
- PMID: 3094242
- DOI: 10.1007/BF00710766
Histomorphometric analysis of osteoclastic bone resorption in metastatic bone disease from various primary malignomas
Abstract
The present study deals with qualitative und quantitative analysis of osteoclastic bone resorption in metastatic bone disease. 267 cases were examined histomorphologically and divided into three developmental stages. In the first 'phase of early appearance' no bone resorption takes place. The stimulation of osteoclastic resorption in the surroundings of tumour tissue is typical in the second 'phase of interaction'. Pressure atrophy, aseptic necrosis and osteolysis by the tumour cells themselves are other mechanisms of bone destruction in the last 'phase of carcinomatosis'. Because osteoclasts are exclusively responsible for the loss of bone tissue in the 'phase of interaction', this stage is suited for precise quantitative analysis of osteoclastic resorption. 24 pure osteolytic secondary bone tumours of various primary lesions were examined histomorphometrically. The numerical values were compared with each other and with standard values of healthy individuals. In contrast with normal bone tissue the fractional resorption surfaces und osteoclast indices increase in metastases. Activated osteoclasts are larger and have more nuclei. The numbers of osteoclast index and nuclei per osteoclast are significantly higher in renal than in breast carcinoma. Osteoclasts can be activated in distances of more than 500 micron from tumour tissue. The mean stimulation distance in metastasis from squamous cell carcinoma is markedly higher than in secondary bone tumours of breast carcinoma. Several osteoclast activating substances and divers mechanisms of stimulation might be responsible for different numerical values of morphometric parameters in metastases from various primary malignancies.
Similar articles
-
Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer.Bone. 1994 Mar-Apr;15(2):161-6. doi: 10.1016/8756-3282(94)90703-x. Bone. 1994. PMID: 8086233
-
Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.Cancer Res. 1998 Feb 1;58(3):462-7. Cancer Res. 1998. PMID: 9458090
-
Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.Clin Cancer Res. 2009 Jun 1;15(11):3751-9. doi: 10.1158/1078-0432.CCR-08-3123. Epub 2009 May 26. Clin Cancer Res. 2009. PMID: 19470728
-
Mechanisms of osteolytic bone destruction.Bone. 1991;12 Suppl 1:S1-6. doi: 10.1016/8756-3282(91)90057-p. Bone. 1991. PMID: 1954046 Review.
-
Molecular mechanisms of tumor-bone interactions in osteolytic metastases.Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78. Crit Rev Eukaryot Gene Expr. 2000. PMID: 11186331 Review.
Cited by
-
Osteoclast Fusion: Physiological Regulation of Multinucleation through Heterogeneity-Potential Implications for Drug Sensitivity.Int J Mol Sci. 2020 Oct 19;21(20):7717. doi: 10.3390/ijms21207717. Int J Mol Sci. 2020. PMID: 33086479 Free PMC article. Review.
-
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals.JBMR Plus. 2020 Sep 29;4(11):e10412. doi: 10.1002/jbm4.10412. eCollection 2020 Nov. JBMR Plus. 2020. PMID: 33210064 Free PMC article.
-
Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.Clin Exp Metastasis. 2000;18(6):463-70. doi: 10.1023/a:1011800919981. Clin Exp Metastasis. 2000. PMID: 11592303
-
The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.PLoS One. 2011 Jan 13;6(1):e16078. doi: 10.1371/journal.pone.0016078. PLoS One. 2011. PMID: 21249149 Free PMC article.
-
Mechanisms involved in the metastasis of cancer to bone.Breast Cancer Res Treat. 1993;25(2):151-63. doi: 10.1007/BF00662140. Breast Cancer Res Treat. 1993. PMID: 8347847 Review.
References
MeSH terms
LinkOut - more resources
Medical